TY - JOUR
T1 - Low Level Antibodies Against Alpha-Tropomyosin Are Associated With Increased Risk of Coronary Heart Disease
AU - Zhang, Yin
AU - Zhao, Heru
AU - Liu, Bin
AU - Li, Li
AU - Zhang, Lulu
AU - Bao, Mei
AU - Ji, Xinyu
AU - He, Xiaojuan
AU - Yi, Jianfeng
AU - Chen, Peng
AU - Lu, Cheng
AU - Lu, Aiping
N1 - Funding Information:
This research has been supported by the National Science and Technology Major Project (2018ZX10101001-005-003 and 2018ZX10101001-005-004) and the Fundamental Research Funds for the Central public welfare research institutes (ZZ11-113 and Z0600). The funding agencies did not have any role in the design and conduct of the study, collection, management, and interpretation of the data or preparation, review, or approval of the manuscript.
Publisher copyright:
© 2020 Zhang, Zhao, Liu, Li, Zhang, Bao, Ji, He, Yi, Chen, Lu and Lu.
PY - 2020/2/27
Y1 - 2020/2/27
N2 - ObjectiveNatural autoantibodies have been implicated to play a key role in the pathogenesis of coronary heart disease (CHD) because they augment autoimmune activation. The aim of this study was to identify novel specific autoantibodies of CHD, and analyze the relationship between their levels and CHD risk indicators. Approach and ResultsFirst, clinical data and sera from CHD patients were collected. Then, one protein microarray containing 37 proteins that represent candidate autoantigens was developed. The arrays were used to profile autoantibodies in randomly selected sera from 35 samples (20 CHD patients, and 15 healthy controls). After that, microarray data were analyzed and autoantibodies for CHD were screened out. Then, ELISA detection was conducted to validate the differentiable autoantibodies using larger numbers of serum samples (131 CHD patients, and 131 healthy controls). Finally, the associations of antibodies with CHD risk indicator parameters were assessed. Inter-group comparison by microarray indicated that three CHD novel autoantibodies, including glucose-6-phosphate isomerase (G6PI), alpha-tropomyosin (TPM1), and heterogeneous nuclear ribonucleoprotein D-like (HnRNPDL), were significantly (P < 0.05) increased when compared with the healthy controls. Moreover, a significant increase of IgG autoantibodies for these three autoantigens was confirmed in CHD patients by ELISA (P < 0.0001). The correction analysis revealed a negative correlation of anti-TPM1 antibody levels and total cholesterol (P = 0.0034), and low-density lipoprotein cholesterol (P = 0.0086), respectively. ConclusionG6PI, TPM1, and HnRNPDL were CHD natural autoantigens, and serum anti-TPM1 antibody could be used as a potential marker to predict the risk for CHD patients.
AB - ObjectiveNatural autoantibodies have been implicated to play a key role in the pathogenesis of coronary heart disease (CHD) because they augment autoimmune activation. The aim of this study was to identify novel specific autoantibodies of CHD, and analyze the relationship between their levels and CHD risk indicators. Approach and ResultsFirst, clinical data and sera from CHD patients were collected. Then, one protein microarray containing 37 proteins that represent candidate autoantigens was developed. The arrays were used to profile autoantibodies in randomly selected sera from 35 samples (20 CHD patients, and 15 healthy controls). After that, microarray data were analyzed and autoantibodies for CHD were screened out. Then, ELISA detection was conducted to validate the differentiable autoantibodies using larger numbers of serum samples (131 CHD patients, and 131 healthy controls). Finally, the associations of antibodies with CHD risk indicator parameters were assessed. Inter-group comparison by microarray indicated that three CHD novel autoantibodies, including glucose-6-phosphate isomerase (G6PI), alpha-tropomyosin (TPM1), and heterogeneous nuclear ribonucleoprotein D-like (HnRNPDL), were significantly (P < 0.05) increased when compared with the healthy controls. Moreover, a significant increase of IgG autoantibodies for these three autoantigens was confirmed in CHD patients by ELISA (P < 0.0001). The correction analysis revealed a negative correlation of anti-TPM1 antibody levels and total cholesterol (P = 0.0034), and low-density lipoprotein cholesterol (P = 0.0086), respectively. ConclusionG6PI, TPM1, and HnRNPDL were CHD natural autoantigens, and serum anti-TPM1 antibody could be used as a potential marker to predict the risk for CHD patients.
KW - autoantibodies
KW - autoantigens
KW - coronary heart disease
KW - protein microarrays
KW - risk factors
UR - http://www.scopus.com/inward/record.url?scp=85082547711&partnerID=8YFLogxK
U2 - 10.3389/fphar.2020.00195
DO - 10.3389/fphar.2020.00195
M3 - Journal article
AN - SCOPUS:85082547711
SN - 1663-9812
VL - 11
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
M1 - 195
ER -
